NASI to divest imaging agent R&D
This article was originally published in The Gray Sheet
Executive Summary
North American Scientific, Inc. will prioritize intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) oncology therapeutics by redirecting a portion of the $10 mil. annual savings that will result from a planned divestiture of its Theseus radiopharmaceutical R&D operation, the firm says. NASI bought Theseus for about $18.5 mil. in 2000; its primary product candidate is the Hynic-Annexin V nuclear imaging agent for determining early response to chemotherapy cancer treatment. Theseus operations and European Phase II lung cancer trials will be suspended Sept. 15 while awaiting sale. NASI expects to take a related $6 mil. charge. Brachytherapy seed maker NASI acquired IMRT/IGRT firm Nomos for about $56 mil. in May (1"The Gray Sheet" Nov. 3, 2003, p. 23)...
You may also be interested in...
Nomos Goes Public Via North American Scientific Merger Valued At $56 Mil.
Radiation oncology firm North American Scientific, Inc. (NASI) will more than triple its revenue to $55-$60 mil. with the purchase of intensity modulated radiation therapy (IMRT) developer Nomos under an Oct. 27 agreement
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.